CA2541903A1 - Methode de diagnostic et de traitement - Google Patents

Methode de diagnostic et de traitement Download PDF

Info

Publication number
CA2541903A1
CA2541903A1 CA002541903A CA2541903A CA2541903A1 CA 2541903 A1 CA2541903 A1 CA 2541903A1 CA 002541903 A CA002541903 A CA 002541903A CA 2541903 A CA2541903 A CA 2541903A CA 2541903 A1 CA2541903 A1 CA 2541903A1
Authority
CA
Canada
Prior art keywords
pkc
cancer
euphorbia
cells
pep005
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002541903A
Other languages
English (en)
Inventor
Steven Martin Ogbourne
Peter Gordon Parsons
Janet Lord
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peplin Research Pty Ltd
Original Assignee
Peplin Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peplin Research Pty Ltd filed Critical Peplin Research Pty Ltd
Priority to CA002541903A priority Critical patent/CA2541903A1/fr
Publication of CA2541903A1 publication Critical patent/CA2541903A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
CA002541903A 2006-04-20 2006-04-20 Methode de diagnostic et de traitement Abandoned CA2541903A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002541903A CA2541903A1 (fr) 2006-04-20 2006-04-20 Methode de diagnostic et de traitement

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002541903A CA2541903A1 (fr) 2006-04-20 2006-04-20 Methode de diagnostic et de traitement

Publications (1)

Publication Number Publication Date
CA2541903A1 true CA2541903A1 (fr) 2007-10-20

Family

ID=38606719

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002541903A Abandoned CA2541903A1 (fr) 2006-04-20 2006-04-20 Methode de diagnostic et de traitement

Country Status (1)

Country Link
CA (1) CA2541903A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012083953A1 (fr) * 2010-12-22 2012-06-28 Leo Pharma A/S Ingénol-3-acylates iii et ingénol-3-carbamates
WO2012085189A1 (fr) * 2010-12-22 2012-06-28 Leo Pharma A/S Ingénol-3-acylates i
WO2012083954A1 (fr) * 2010-12-22 2012-06-28 Leo Pharma A/S 3-acyl-ingénols ii
CN102597778A (zh) * 2009-10-30 2012-07-18 学校法人庆应义塾 抗癌剂感受性的判定方法
RU2575349C2 (ru) * 2010-12-22 2016-02-20 Лео Лэборетериз Лимитед Ингенол-3-ацилаты i
KR101914460B1 (ko) 2010-07-20 2018-11-05 레오 라보라토리즈 리미티드 인게놀-3-안젤레이트의 제조방법

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102597778B (zh) * 2009-10-30 2016-03-02 学校法人庆应义塾 抗癌剂感受性的判定方法
CN102597778A (zh) * 2009-10-30 2012-07-18 学校法人庆应义塾 抗癌剂感受性的判定方法
US9459254B2 (en) 2009-10-30 2016-10-04 Keio University Method for determining sensitivity to an anticancer agent
EP3640236A1 (fr) * 2010-07-20 2020-04-22 Leo Laboratories Limited Procédés de production d'ingénol-3-angélate
EP2595948B1 (fr) * 2010-07-20 2019-09-04 Leo Laboratories Limited Procédé de production d'ingénol-3-angélate
KR101914460B1 (ko) 2010-07-20 2018-11-05 레오 라보라토리즈 리미티드 인게놀-3-안젤레이트의 제조방법
RU2572549C2 (ru) * 2010-12-22 2016-01-20 Лео Лэборетериз Лимитед Ингенол-3-ацилаты iii и ингенол-3-карбаматы
US9388124B2 (en) 2010-12-22 2016-07-12 Leo Laboratories Limited Ingenol-3-acylates I
US9102687B2 (en) 2010-12-22 2015-08-11 Leo Laboratories Limited Ingenol-3-acylates III and ingenol-3-carbamates
AU2011348637B2 (en) * 2010-12-22 2015-08-20 Leo Laboratories Limited Ingenol-3-acylates III and ingenol-3-carbamates
WO2012083953A1 (fr) * 2010-12-22 2012-06-28 Leo Pharma A/S Ingénol-3-acylates iii et ingénol-3-carbamates
RU2575349C2 (ru) * 2010-12-22 2016-02-20 Лео Лэборетериз Лимитед Ингенол-3-ацилаты i
RU2575350C2 (ru) * 2010-12-22 2016-02-20 Лео Лэборетериз Лимитед 3-ацилингенолы ii
JP2014512331A (ja) * 2010-12-22 2014-05-22 レオ・ラボラトリーズ・リミテッド インゲノール−３−アシラートｉｉｉおよびインゲノール−３−カルバメート
JP2016029081A (ja) * 2010-12-22 2016-03-03 レオ・ラボラトリーズ・リミテッドＬｅｏ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ インゲノール−３−アシラートｉｉｉおよびインゲノール−３−カルバメート
AU2011348638B2 (en) * 2010-12-22 2015-05-21 Leo Laboratories Limited 3-acyl-ingenols II
JP2014507393A (ja) * 2010-12-22 2014-03-27 レオ・ラボラトリーズ・リミテッド ３−アシル−イノゲノールｉｉ
AU2015210441B2 (en) * 2010-12-22 2016-10-06 Leo Laboratories Limited Ingenol-3-acylates iii and ingenol-3-carbamates
US9656945B2 (en) 2010-12-22 2017-05-23 Leo Laboratories Limited 3-acyl-ingenols II
US9708286B2 (en) 2010-12-22 2017-07-18 Leo Laboratories Limited Ingenol-3-acylates III and ingenol-3-carbamates
JP2014507396A (ja) * 2010-12-22 2014-03-27 レオ・ラボラトリーズ・リミテッド イノゲノール−３−アシラートｉ
WO2012083954A1 (fr) * 2010-12-22 2012-06-28 Leo Pharma A/S 3-acyl-ingénols ii
WO2012085189A1 (fr) * 2010-12-22 2012-06-28 Leo Pharma A/S Ingénol-3-acylates i

Similar Documents

Publication Publication Date Title
Xu et al. Breast cancer susceptibility protein 1 (BRCA1) rescues neurons from cerebral ischemia/reperfusion injury through NRF2-mediated antioxidant pathway
Jiang et al. Anti-tumor effects of osthole on ovarian cancer cells in vitro
JP4868403B2 (ja) アシュワガンダの葉抽出物による腫瘍細胞選択的増殖阻害
Xie et al. The protective effect of resveratrol in the transmission of neuropathic pain mediated by the P2X7 receptor in the dorsal root ganglia
CA2541903A1 (fr) Methode de diagnostic et de traitement
Wang et al. Astrocytic CCAAT/Enhancer-binding protein delta contributes to reactive oxygen species formation in neuroinflammation
US20080069809A1 (en) Compositions and methods for the diagnosis and treatment of cancer
Zhang et al. Inhibiting Jumoji domain containing protein 3 (JMJD3) prevent neuronal apoptosis from stroke
Wang et al. Total flavonoid aglycones extract in Radix scutellariae inhibits lung carcinoma and lung metastasis by affecting cell cycle and DNA synthesis
Chen et al. CysLT2 receptor mediates lipopolysaccharide-induced microglial inflammation and consequent neurotoxicity in vitro
Cai et al. Allicin alleviated learning and memory deficits caused by lead exposure at developmental stage
Zhang et al. Hypoxic preconditioning protects cardiomyocytes against hypoxia/reoxygenation-induced cell apoptosis via sphingosine kinase 2 and FAK/AKT pathway
Zhou et al. Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway
Korinek et al. Randialic acid B and tomentosolic acid block formyl peptide receptor 1 in human neutrophils and attenuate psoriasis-like inflammation in vivo
US8889672B2 (en) Compounds, formulations, and methods of protein kinase C inhibition
Shen et al. Methyl palmitate protects heart against ischemia/reperfusion-induced injury through G-protein coupled receptor 40-mediated activation of the PI3K/AKT pathway
KR20180032506A (ko) 티오레독신 결합단백질 유래 펩타이드 또는 이를 암호화 하는 폴리뉴클레오타이드를 유효성분으로 함유하는 노화 줄기세포의 역노화용 조성물 및 이의 용도
AU2006201661A1 (en) A method of diagnosis and treatment
JP2014129341A (ja) マルチキナーゼ阻害剤、抗癌剤、抗転移剤、薬剤耐性抑制剤、疼痛抑制剤及び止痒薬
AU2015352041B2 (en) Titled extracts of Cynara scolymus and uses thereof
CN101940569A (zh) 含有索拉非尼和青蒿素及青蒿素类衍生物的药物组合物及其在制备治疗癌症的药物中的应用
Wu et al. Ginsenoside Rh2 inhibits CBP/p300-mediated FOXO3a acetylation and epilepsy-induced oxidative damage via the FOXO3a–KEAP1–NRF2 pathway
KR101186264B1 (ko) 산자나무 추출물 또는 이로부터 분리된 화합물을 포함하는 ｉｌ-6으로 매개되는 질환 또는 라이노바이러스 감염성 질환의 예방 또는 치료용 조성물
JP5985292B2 (ja) Ｔｒｐｖ４活性抑制剤
KR101678791B1 (ko) p53 돌연변이성 고형암 및 탁솔 내성 고형암 치료제로서의 제니스테인의 항암제 용도

Legal Events

Date Code Title Description
FZDE Dead